AbbVie | ABBV - Operating Expenses



AbbVie reported $9.71B in Operating Expenses for its fiscal quarter ending in June of 2025.


Operating Expenses Change Date
AbbVie USD 9.71B 96M Jun/2025
Abbott USD 9.07B 369M Jun/2025
ALKERMES USD 297.68M 4.96M Jun/2025
Amgen USD 6.52B 337M Jun/2025
AstraZeneca USD 10.95B 1.04B Jun/2025
Biogen USD 1.79B 326.1M Jun/2025
BioMarin Pharmaceutical USD 548.52M 27.27M Jun/2025
Bristol-Myers Squibb USD 8.5B 265M Jun/2025
Eisai JPY 181.91B 7.35B Jun/2025
Eli Lilly USD 8.54B 1.22B Jun/2025
Gilead Sciences USD 4.35B 80M Jun/2025
GlaxoSmithKline GBP 5.96B 663M Jun/2025
J&J USD 16.8B 8.54B Jun/2025
Medtronic USD 7.06B 430M Jul/2025
Merck USD 9.44B 217M Jun/2025
Neurocrine Biosciences USD 541.9M 7M Jun/2025
Novartis USD 9.97B 1.02B Jun/2025
Pacira USD 170.87M 3.93M Jun/2025
Perrigo USD 1B 36.2M Jun/2025
Pfizer USD 11.62B 1.58B Jun/2025
Regeneron Pharmaceuticals USD 2.6B 159.1M Jun/2025
Roche Holding CHF 11.43B 1.48B Dec/2024
Sanofi EUR 9.02B 702M Jun/2025
UCB EUR 2.36B 108M Dec/2024
Ultragenyx Pharmaceutical USD 274.38M 7.85M Jun/2025
United Therapeutics USD 521.7M 110.1M Jun/2025
Vertex Pharmaceuticals USD 1.81B 71.4M Jun/2025
Zoetis USD 1.44B 35M Jun/2025